Request Discount

Conjugate Vaccine Market (Type - Monovalent Conjugate Vaccines, and Multivalent Conjugate Vaccines; Disease Indication - Influenza, Diphtheria and Pertussis (DTP), Pneumococcal, Meningococcal, and Other Disease Indication; Pathogen Type - Viral Conjugate Vaccine, Bacterial Conjugate Vaccine, and Combination (Viral and Bacterial) Conjugate Vaccine; End User - Adults Conjugate Vaccine, and Pediatrics Conjugate Vaccine): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : July, 2019

  • Rep Id : HC0591

  • Category : Healthcare & Medical Devices

  • Status : Published

This report provides exclusive insights into the COVID-19 impact on the Conjugate Vaccine Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Conjugate Vaccine Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Conjugate Vaccine Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.

A recent report published by Infinium Global Research on conjugate vaccine market provides in-depth analysis of segments and sub-segments in the global as well as regional conjugate vaccine market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional conjugate vaccine market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global conjugate vaccine market. According to the report, the global conjugate vaccine market is projected to grow at a CAGR of 9.5% over the forecast period of 2019-2025.

Market Insight

The main role of the vaccine is to prevent diseases by activating an immune response to an antigen. Conjugate vaccine is made to overcome the short term immune response. Conjugate vaccine is the combination of weak antigen with a strong antigen. The weak antigen is combined as a carrier, it makes a stronger immune response to the weak antigen.

The increasing number of viral infection globally is one of the major drivers for the growth of conjugate vaccine market. According to WHO prevalence of viral diseases such as influenza, childhood viral pneumonia, and hepatitis has increased significantly in the last decade. Increasing antigenicity of viral pathogens is also supporting the growth of conjugate vaccine market. Moreover, rising government initiatives for the vaccination program is another factor fuelling the conjugate vaccine market. Most of the developing and developed countries have applied stringent regulations for the vaccination to control the prevalence of viral diseases worldwide that in turn is contributing to the growth of the conjugate vaccine market. On the other hand, the high cost associated with the vaccines and lack of government centers for vaccination in developing countries can hamper the growth of the market. However, increasing awareness about viral diseases globally can provide better opportunities for the market in the forecast period.

Geographically, the conjugate Vaccine market is segmented by North America, Europe, Asia Pacific, and RoW. North America dominates the Conjugate Vaccine market and expected keep to its dominance over the forecast period. Presence of major biotech companies, increasing research and development activities for effective vaccine production and growing awareness about immunization programs among people are some of the factor contributing to the growth of the market in this region. Europe is anticipated to register healthy growth in the forecast period. Whereas, Asia-Pacific is expected to grow with a lucrative rate in the forecast period. Growing prevalence of the viral disease, initiatives by major pharma players in this region for vaccine production, and rising government initiatives for immunization programs have expected to boost the Conjugate Vaccine market in this region.

Segment Covered

The report on global conjugate vaccine market covers segments such as type, disease indication, pathogen type, and end user. On the basis of type, the sub-markets include monovalent conjugate vaccines, and multivalent conjugate vaccines. On the basis of disease indication, the sub-markets include influenza, diphtheria and pertussis (DTP), pneumococcal, meningococcal, and other disease indication. On the basis of pathogen type, the sub-markets include viral conjugate vaccine, bacterial conjugate vaccine, and combination (viral and bacterial) conjugate vaccine. On the basis of end user, the sub-markets include adults conjugate vaccine, and pediatrics conjugate vaccine. 

Companies Profiled:

The report provides profiles of the companies in the market such as Serum Institute of India, Novartis AG, Nuron Biotech Inc., Sanofi Pasteur, Bharat Biotech, Pfizer, Inc., Biological E. Ltd, Merck and Company, CSL Limited, GlaxoSmithKline, plc., and Other companies. 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of conjugate vaccine market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount